Premanufacture Notices (PMNs) and Significant New Use Notices (SNUNs) Table

Recommended section 5(e) Consent Order - Insufficient information available to permit a reasoned evaluation of the health effects

'Not likely to present an unreasonable risk' section 5(a)(3)(C) determination’

*In EPA's original screening analysis for this PMN in 2017, EPA identified potential for risk to workers, which resulted in the interim finding. EPA's final determination that the chemical substance is not likely to present unreasonable risk is based on EPA's risk assessment for the chemical substance under the intended and reasonably foreseen conditions of use where EPA expects that workers will use appropriate personal protective equipment, consistent with the Safety Data Sheet (SDS) prepared by the PMN submitter, in a manner adequate to protect them.

'Not likely to present an unreasonable risk' section 5(a)(3)(C) determination^*

*In 2016, EPA’s original screening analysis for this PMN resulted in the interim finding listed to the Interim Status column. In response to EPA’s recommendation, the submitter requested EPA perform an assessment using read-across for a particular analogue (an acrylamide). In considering the submitter’s request, EPA identified additional analogues which it deemed more predictive (acrylates) than the submitter’s suggested analogue for conducting a reasoned evaluation for the PMN substance. EPA conducted risk evaluation with both analogues and based on the analogue EPA deemed most predictive concluded the PMN substance was not likely to present unreasonable risk. Additional details regarding the analogues and risk evaluation are provided in the Determination document.